<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35248124</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1750-1326</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular neurodegeneration</Title>
          <ISOAbbreviation>Mol Neurodegener</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Alzheimer's disease - the journey of a healthy brain into organ failure.</ArticleTitle>
        <Pagination>
          <StartPage>18</StartPage>
          <MedlinePgn>18</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">18</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-022-00523-1</ELocationID>
        <Abstract>
          <AbstractText>As the most common dementia, Alzheimer's disease (AD) exacts an immense personal, societal, and economic toll. AD was first described at the neuropathological level in the early 1900s. Today, we have mechanistic insight into select aspects of AD pathogenesis and have the ability to clinically detect and diagnose AD and underlying AD pathologies in living patients. These insights demonstrate that AD is a complex, insidious, degenerative proteinopathy triggered by Aβ aggregate formation. Over time Aβ pathology drives neurofibrillary tangle (NFT) pathology, dysfunction of virtually all cell types in the brain, and ultimately, overt neurodegeneration. Yet, large gaps in our knowledge of AD pathophysiology and huge unmet medical need remain. Though we largely conceptualize AD as a disease of aging, heritable and non-heritable factors impact brain physiology, either continuously or at specific time points during the lifespan, and thereby alter risk for devolvement of AD. Herein, I describe the lifelong journey of a healthy brain from birth to death with AD, while acknowledging the many knowledge gaps that remain regarding our understanding of AD pathogenesis. To ensure the current lexicon surrounding AD changes from inevitable, incurable, and poorly manageable to a lexicon of preventable, curable, and manageable we must address these knowledge gaps, develop therapies that have a bigger impact on clinical symptoms or progression of disease and use these interventions at the appropriate stage of disease.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Golde</LastName>
            <ForeName>Todd E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Neuroscience and Neurology, Evelyn F. and William L. McKnight Brain Institute, Norman Fixel Institute for Neurological Diseases, Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, Fl, USA. tgolde@ufl.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30AG066506</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01AG046139</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1AG057933</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1AG064942</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RF1AG064914</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG062514</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Neurodegener</MedlineTA>
        <NlmUniqueID>101266600</NlmUniqueID>
        <ISSNLinking>1750-1326</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Alzheimer’s Disease</Keyword>
        <Keyword MajorTopicYN="Y">Amyloid</Keyword>
        <Keyword MajorTopicYN="Y">Neurodegeneration</Keyword>
        <Keyword MajorTopicYN="Y">Organ failure</Keyword>
        <Keyword MajorTopicYN="Y">Proteinopathy</Keyword>
        <Keyword MajorTopicYN="Y">Risk factors</Keyword>
        <Keyword MajorTopicYN="Y">Tau</Keyword>
      </KeywordList>
      <CoiStatement>TEG is a co-founder of Lacerta Therapeutics Inc and Andante Biologics Inc. He has served on advisory boards for Eli Lilly, BMS, Novartis, Abbvie, Lundbeck, Pfizer, and Promis Neurosciences Inc. Dr. Golde is an associate editor of Molecular neurodegeneration.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>6</Day>
          <Hour>20</Hour>
          <Minute>25</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35248124</ArticleId>
        <ArticleId IdType="pmc">PMC8898417</ArticleId>
        <ArticleId IdType="doi">10.1186/s13024-022-00523-1</ArticleId>
        <ArticleId IdType="pii">10.1186/s13024-022-00523-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Fischer O. Miliaere Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmassige Veraenderung der Hirnrinde bei seniler Demenz. Monatsschr Psychiat Neurol. 1907;22:361–372.</Citation>
        </Reference>
        <Reference>
          <Citation>Fischer O. Ein weiterer Beitrag zur Klinik und Pathologie der presbyophrenen Demenz. Z ges Neruol Psychiat. 1912;12:99–135.</Citation>
        </Reference>
        <Reference>
          <Citation>Fischer O. Die presbyophrene Demenz, deren anatomische Grundlage und klinische Abgrenzung, Z ges Neurol Psychiat. 1910;3:371–471.</Citation>
        </Reference>
        <Reference>
          <Citation>Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiat Psych-Gericht Med. 1907;64:146–148.</Citation>
        </Reference>
        <Reference>
          <Citation>Amaducci LA, Rocca WA, Schoenberg BS. Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosology. Neurology. 1986;36:1497–1499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3531918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beach TG. The history of Alzheimer's disease: three debates. J Hist Med Allied Sci. 1987;42:327–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3305698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert M. Oskar Fischer and the study of dementia. Brain. 2009;132:1102–1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2668940</ArticleId>
            <ArticleId IdType="pubmed">18952676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging. 1998;19:173–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9661992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>2021 Alzheimer's disease facts and figures. Alzheimer's Dement. 2021;17:327–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33756057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reitz C, Brayne C, Mayeux R: Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3339565</ArticleId>
            <ArticleId IdType="pubmed">21304480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong CW, Quaranta V, Glenner GG. Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc Natl Acad Sci USA. 1985;82:8729–8732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC391510</ArticleId>
            <ArticleId IdType="pubmed">2934737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122:1131–1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6236805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 1985;4:2757–2763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC554575</ArticleId>
            <ArticleId IdType="pubmed">4065091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA. 1985;82:4245–4249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC397973</ArticleId>
            <ArticleId IdType="pubmed">3159021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85:4051–4055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC280359</ArticleId>
            <ArticleId IdType="pubmed">3131773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosik KS, Orrechio LD, Binder L, Trojanowski JQ. Lee VM-Y, Lee G: Epitopes that nearly span the tau molecule are shared with paired helical filaments. Neuron. 1988;1:817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2483104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3130546</ArticleId>
            <ArticleId IdType="pubmed">21471435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology. 2013;12:207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622225</ArticleId>
            <ArticleId IdType="pubmed">23332364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14:32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6679484</ArticleId>
            <ArticleId IdType="pubmed">31375134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Alzheimer's Disease Neuroimaging I: Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68:1257–1266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5604752</ArticleId>
            <ArticleId IdType="pubmed">21670386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355–1365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677798</ArticleId>
            <ArticleId IdType="pubmed">19339253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Alzheimer's Disease Neuroimaging I: Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310–1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2677792</ArticleId>
            <ArticleId IdType="pubmed">19042931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, et al.  Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain. 2012;135:2126–2139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22628162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chetelat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013;2:356–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3777672</ArticleId>
            <ArticleId IdType="pubmed">24179789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1566067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12130773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE. Alzheimer disease therapy: Can the amyloid cascade be halted? J Clin Invest. 2003;111:11–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC151845</ArticleId>
            <ArticleId IdType="pubmed">12511580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer's disease in twins. Biomed Pharmacother. 1997;51:101–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9181044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanzi RE: The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3475404</ArticleId>
            <ArticleId IdType="pubmed">23028126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rocca WA, Amaducci L. The familial aggregation of Alzheimer's disease: an epidemiological review. Psychiatr Dev. 1988;6:23–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3050982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dourlen P, Kilinc D, Malmanche N, Chapuis J, Lambert JC. The new genetic landscape of Alzheimer's disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol. 2019;138:221–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6660578</ArticleId>
            <ArticleId IdType="pubmed">30982098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, et al.  Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6463297</ArticleId>
            <ArticleId IdType="pubmed">30820047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al.  Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017;49:1373–1384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5669039</ArticleId>
            <ArticleId IdType="pubmed">28714976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellenguez C, Grenier-Boley B, Lambert JC. Genetics of Alzheimer's disease: where we are, and where we are going. Curr Opin Neurobiol. 2020;61:40–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31863938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12130773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088–1093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2845877</ArticleId>
            <ArticleId IdType="pubmed">19734902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, et al.  Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41:1308–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2787725</ArticleId>
            <ArticleId IdType="pubmed">19915575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al.  TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368:117–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3631573</ArticleId>
            <ArticleId IdType="pubmed">23150934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karch CM, Goate AM. Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis. Biol Psychiat. 2015;77:43–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4234692</ArticleId>
            <ArticleId IdType="pubmed">24951455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8346443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saunders AM, Schmader K, Breitner JCS, Benson MD, Brown WT, Goldfarb A, Goldgaber D, Manwaring MG, Szymanski MH, McCown N, et al.  Apolipoprotein E e4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet. 1993;342:710–711.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8103823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet. 1998;32:461–493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9928488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, Rongve A, Borte S, Winsvold BS, Drange OK, et al.  A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet. 2021;53:1276–1282.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34493870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Broeckhoven C, Haan J, Bakker E, Hardy JA, Van Hul W, Wehnert A. Vegter-Van der Vlis M, Roos RA: Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch) Science. 1990;248:1120–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1971458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of ß-amyloid. Nat Genet. 1992;1:345–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1302033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al.  Segregation of a missense mutation in the amyloid precursor gene with familial Alzheimer's disease. Nature. 1991;349:704–706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1671712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goate AM, Owen MJ, James LA, Mullan MJ, Rossor MN, Haynes AR, Farrall M, Lai LYC, Roques P, Williamson R, Hardy JA: Predisposing locus for Alzheimer's disease on chromosome 21. The Lancet 1989:352–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2563508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chartier-Harlin M-C, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, Mullan M. Early-onset Alzheimer's Disease caused by mutations at codon 717 of the ß-amyloid precursor protein gene. Nature. 1991;353:844–846.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1944558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanzi RE, Gusella JF, Watkins PC, et al.  e: Amyloid ß protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus. Science. 1987;235:880–884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2949367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robakis NK, Ramakrishna N, Wolfe G, Wisniewski HM. Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. Proc Natl Acad Sci USA. 1987;84:4190–4194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305050</ArticleId>
            <ArticleId IdType="pubmed">3035574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robakis NK, Wisniewski HM, Jenkins EC, Devine-Gage EA, Houck GE, Yao X-L, Ramakrishna N, Wolfe G, Silverman WP, Brown WT. Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet. 1987;14:384–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2880184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733–736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2881207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyrks T, Weidemann A, Multhaup G, Salbaum JM, Lemaire H-G, Kang J, Müller-Hill B, Masters CL, Beyreuther K. Identification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease. EMBO J. 1988;7:949–957.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC454420</ArticleId>
            <ArticleId IdType="pubmed">2900137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broeckhoven CV. Presenilins and Alzheimer-disease. Nature Genet. 1995;11:230–232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7581440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark R, Hutton M, Fuldner R, Froelich S, Hardy J, Goate A. The structure of the presenilin-1 (S182) gene and identification of 6 novel mutations in early-onset AD families. Nature Gentics. 1995;0011:219–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7550356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu C, Jondro PD, Schmidt SD, Wang K, et al.  Candidate gene for the Chromsome 1 Familial Alzheimer's Disease Locus. Science. 1995;269:973–977.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7638622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KAB, Weber JL, Bird TD, Schellenberg GD. A Familial Alzheimer's Disease Locus on chromosome 1. Science. 1995;269:970–973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7638621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368:107–116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677583</ArticleId>
            <ArticleId IdType="pubmed">23150908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, et al.  A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22801501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis. 1997;4:170–185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9361294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, Myers AJ, Hardy J, et al.  Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6997393</ArticleId>
            <ArticleId IdType="pubmed">32015339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, et al.  Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–1683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6898984</ArticleId>
            <ArticleId IdType="pubmed">31686034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez I, Gelpi E, Molina-Porcel L, Bernal S, Rodriguez-Santiago B, Dols-Icardo O, Ruiz A, Alcolea D, Boada M, Lleo A, Clarimon J. Heterozygous APOE Christchurch in familial Alzheimer's disease without mutations in other Mendelian genes. Neuropathol Appl Neurobiol. 2021;47:579–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33095930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, et al.  ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener. 2014;9:11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3995879</ArticleId>
            <ArticleId IdType="pubmed">24607147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020;15:40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7364557</ArticleId>
            <ArticleId IdType="pubmed">32677986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai XD, Golde TE, Younkin SG. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor [see comments] Science. 1993;259:514–516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8424174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ. Mutation of the ß-amyloid precursor protein in familial Alzheimer's disease increases ß-protein production. Nature. 1992;360:672–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1465129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16369530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann DM. Alzheimer's disease and Down's syndrome. Histopathology. 1988;13:125–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2971602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki N, Cheung TT, Cai X-D, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG. An increased percentage of long amyloid ß protein is secreted by familial amyloid ß protein precursor (ßAPP717) mutants. Science. 1994;264:1336–1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8191290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn PH, Kremmer E, Giese A, Lichtenthaler SF, Haass C, Arzberger T, Steiner H. Generation and deposition of Abeta43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease. EMBO Mol Med. 2016;8:458–465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5119496</ArticleId>
            <ArticleId IdType="pubmed">26988102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease [see comments] Nat Med. 1996;2:864–870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8705854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, Capell A, Walter J, Grunberg J, Haass C, et al.  The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue [see comments] Proc Natl Acad Sci USA. 1997;94:2025–2030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC20036</ArticleId>
            <ArticleId IdType="pubmed">9050898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, et al.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005–1013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8938131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, vanDuinen SG, Bots GTAM, Luyendijk W, Frangione B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage. Dutch type Science. 1990;248:1124–1126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2111584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochemical Journal. 1995;306:599–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1136559</ArticleId>
            <ArticleId IdType="pubmed">7534068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887–893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11528419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Coble D, McDade EM, Hassenstab J, Fagan AM, Benzinger TLS, Bateman RJ, Morris JC, Xiong C. Dominantly Inherited Alzheimer N: Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. Alzheimers Dement. 2019;15:506–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6461496</ArticleId>
            <ArticleId IdType="pubmed">30773445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69:203–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3058906</ArticleId>
            <ArticleId IdType="pubmed">21262461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNamara MJ, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. Arch Neurol. 1998;55:1001–1004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9678319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000;47:739–747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10852539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278:1349–1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9343467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892–2897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16026</ArticleId>
            <ArticleId IdType="pubmed">10694577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2002;9:305–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11950276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fleisher AS, Chen K, Liu X, Ayutyanont N, Roontiva A, Thiyyagura P, Protas H, Joshi AD, Sabbagh M, Sadowsky CH, et al.  Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging. 2013;34:1–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22633529</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alzheimer’s Disease Neuroimaging Initiative. Bangen KJ, Clark AL, Werhane M, Edmonds EC, Nation DA, Evangelista N, Libon DJ, Bondi MW, Delano-Wood L. Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE ɛ4 Genotype. J Alzheimer's Dis. 2016;52:849–861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4884141</ArticleId>
            <ArticleId IdType="pubmed">27031472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, et al.  APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry. 2015;20:1322–1328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4759101</ArticleId>
            <ArticleId IdType="pubmed">25288138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, et al.  Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79:1645–1652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23071163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, Ivnik RJ, Preboske GM, Roberts R, Geda YE, Boeve BF, et al.  APOE modifies the association between Abeta load and cognition in cognitively normal older adults. Neurology. 2012;78:232–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3280056</ArticleId>
            <ArticleId IdType="pubmed">22189452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Josephs KA, Duffy JR, Strand EA, Machulda MM, Senjem ML, Lowe VJ, Jack CR, Jr, Whitwell JL. APOE epsilon4 influences beta-amyloid deposition in primary progressive aphasia and speech apraxia. Alzheimers Dement. 2014;10:630–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4254054</ArticleId>
            <ArticleId IdType="pubmed">24985533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buckley RF, Mormino EC, Amariglio RE, Properzi MJ, Rabin JS, Lim YY, Papp KV, Jacobs HIL, Burnham S, Hanseeuw BJ, et al.  Sex, amyloid, and APOE epsilon4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement. 2018;14:1193–1203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6131023</ArticleId>
            <ArticleId IdType="pubmed">29803541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, et al.  Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer's disease. Alzheimers Dement. 2018;14:913–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29601787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science. 1992;258:126–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1439760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al.  Amyloid beta-peptide is produced by cultured cells during normal metabolism [see comments] Nature. 1992;359:322–325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1383826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindelhurst C, et al.  Isolation and quantitation of soluble Alzheimer's ß-peptide from biological fluids. Nature. 1992;359:325–327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1406936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vassar R, Bennett B, Babu-Khan S, Rogers G, Citron M. Beta-Secretase celavage of Alzheimer's Amyloid Precursor Protein by the transmembrane aspartic protease BACE. Science. 1999;286:735–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10531052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al.  Purification and cloning of amyloid precursor protein beta-secretase from human brain [In Process Citation] Nature. 1999;402:537–540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10591214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor [In Process Citation] Science. 2000;290:150–153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11021803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6:99–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2879045</ArticleId>
            <ArticleId IdType="pubmed">20139999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haass C, De Strooper B. The presenilins in Alzheimer's disease–proteolysis holds the key. Science. 1999;286:916–919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10542139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edbauer D, Winkler E, Haass C, Steiner H. Presenilin and nicastrin regulate each other and determine amyloid beta- peptide production via complex formation. Proc Natl Acad Sci U S A. 2002;99:8666–8671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC124353</ArticleId>
            <ArticleId IdType="pubmed">12048259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A. 2002;99:2720–2725.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC122414</ArticleId>
            <ArticleId IdType="pubmed">11867728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Y, Ye Y, Fortini ME. Nicastrin is required for gamma-secretase cleavage of the Drosophila Notch receptor. Dev Cell. 2002;2:69–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopan R, Goate A. Aph-2/Nicastrin: an essential component of gamma-secretase and regulator of Notch signaling and Presenilin localization. Neuron. 2002;33:321–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11832221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma- Secretase complex. Neuron. 2003;38:9–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12691659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5:486–488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12679784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042–13052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6665297</ArticleId>
            <ArticleId IdType="pubmed">19828817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE, Eckman CB, Younkin SG. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim Biophys Acta. 2000;1502:172–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10899442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE. The pathogenesis of Alzheimer's disease and the role of Abeta42. CNS Spectr. 2007;12:4–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17192766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarrett JT, Berger EP., Jr PTL: The carboxy terminus of ß amyloid protein is critical for the seeding of amyloid formation: Implications for pathogenesis of Alzheimer's disease. Biochem. 1993;32:4693–4697.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8490014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarrett JT., Jr PTL: Seeding “one dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and Scrapie? Cell. 1993;73:1055–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8513491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with and-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8043280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr, Younkin LH, Suzuki N, Younkin SG. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43) J Biol Chem. 1995;270:7013–7016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7706234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, et al.  Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005;47:191–199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1373682</ArticleId>
            <ArticleId IdType="pubmed">16039562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E. Abeta40 inhibits amyloid deposition in vivo. J Neurosci. 2007;27:627–633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6672801</ArticleId>
            <ArticleId IdType="pubmed">17234594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Nostrand WE, Melchor JP, Romanov G, Zeigler K, Davis J. Pathogenic effects of cerebral amyloid angiopathy mutations in the amyloid beta-protein precursor. Ann N Y Acad Sci. 2002;977:258–265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12480759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16:30–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7268202</ArticleId>
            <ArticleId IdType="pubmed">31827267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Zhou Q, Ni Y, Le W. Autophagy and Alzheimer's Disease. Adv Exp Med Biol. 2020;1207:3–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32671736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Small SA, Petsko GA: Endosomal recycling reconciles the Alzheimer's disease paradox. Sci Transl Med 2020, 12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8025181</ArticleId>
            <ArticleId IdType="pubmed">33268506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31:2729–2743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6137496</ArticleId>
            <ArticleId IdType="pubmed">28663518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwart D, Gregg A, Scheckel C, Murphy EA, Paquet D, Duffield M, Fak J, Olsen O, Darnell RB, Tessier-Lavigne M. A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP beta-CTFs, Not Abeta. Neuron. 2019;104:256–270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31416668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert JC, Grenier-Boley B, Chouraki V, Heath S, Zelenika D, Fievet N, Hannequin D, Pasquier F, Hanon O, Brice A, et al.  Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis. 2010;20:1107–1118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20413860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501–518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7055192</ArticleId>
            <ArticleId IdType="pubmed">31367008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179:312–339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6778042</ArticleId>
            <ArticleId IdType="pubmed">31564456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5641217</ArticleId>
            <ArticleId IdType="pubmed">28959956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020;15:63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7640652</ArticleId>
            <ArticleId IdType="pubmed">33148290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dean DC, 3rd, Jerskey BA, Chen K, Protas H, Thiyyagura P, Roontiva A, O'Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, et al.  Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014;71:11–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4056558</ArticleId>
            <ArticleId IdType="pubmed">24276092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Ulland TK, Colonna M. TREM2-Dependent Effects on Microglia in Alzheimer's Disease. Front Aging Neurosci. 2018;10:202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6046445</ArticleId>
            <ArticleId IdType="pubmed">30038567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the Role of TREM2 in Alzheimer's Disease. Neuron. 2017;94:237–248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28426958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE. Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. Neuron. 2019;101:1003–1015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6594693</ArticleId>
            <ArticleId IdType="pubmed">30897353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takalo M, Wittrahm R, Wefers B, Parhizkar S, Jokivarsi K, Kuulasmaa T, Makinen P, Martiskainen H, Wurst W, Xiang X, et al.  The Alzheimer's disease-associated protective Plcgamma2-P522R variant promotes immune functions. Mol Neurodegener. 2020;15:52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7488484</ArticleId>
            <ArticleId IdType="pubmed">32917267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magno L, Lessard CB, Martins M, Lang V, Cruz P, Asi Y, Katan M, Bilsland J, Lashley T, Chakrabarty P, et al.  Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimers Res Ther. 2019;11:16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6359863</ArticleId>
            <ArticleId IdType="pubmed">30711010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleineidam L, Chouraki V, Prochnicki T, van der Lee SJ, Madrid-Marquez L, Wagner-Thelen H, Karaca I, Weinhold L, Wolfsgruber S, Boland A, et al.  PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. Acta Neuropathol. 2020;139:1025–1044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7244617</ArticleId>
            <ArticleId IdType="pubmed">32166339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, et al: High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med 2018, 10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6220267</ArticleId>
            <ArticleId IdType="pubmed">30341064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Itzhaki RF, Golde TE, Heneka MT, Readhead B. Do infections have a role in the pathogenesis of Alzheimer disease? Nat Rev Neurol. 2020;16:193–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32152461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venegas C, Heneka MT. Danger-associated molecular patterns in Alzheimer's disease. J Leukoc Biol. 2017;101:87–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28049142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern Y, Barnes CA, Grady C, Jones RN, Raz N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol Aging. 2019;83:124–129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6859943</ArticleId>
            <ArticleId IdType="pubmed">31732015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartres-Faz D, Arenaza-Urquijo E, Ewers M, Belleville S, Chetelat G, Franzmeier N, Gonneaud J, de Echevarri JMG, Okonkwo O, Schultz S, et al.  Theoretical frameworks and approaches used within the Reserve, Resilience and Protective Factors professional interest area of the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment. Alzheimers Dement (Amst) 2020;12:e12115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7656169</ArticleId>
            <ArticleId IdType="pubmed">33204812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, Nagel M, Awasthi S, Barr PB, Coleman JRI, et al.  Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet. 2018;50:912–919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6411041</ArticleId>
            <ArticleId IdType="pubmed">29942086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–2263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25771249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehtisalo J, Levalahti E, Lindstrom J, Hanninen T, Paajanen T, Peltonen M, Antikainen R, Laatikainen T, Strandberg T, Soininen H, et al.  Dietary changes and cognition over 2 years within a multidomain intervention trial-The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) Alzheimers Dement. 2019;15:410–417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30527596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulmala J, Ngandu T, Havulinna S, Levalahti E, Lehtisalo J, Solomon A, Antikainen R, Laatikainen T, Pippola P, Peltonen M, et al.  The Effect of Multidomain Lifestyle Intervention on Daily Functioning in Older People. J Am Geriatr Soc. 2019;67:1138–1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30809801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl D, Solon-Biet SM, Cogger VC, Fontana L, Simpson SJ, Le Couteur DG, Ribeiro RV. Aging, lifestyle and dementia. Neurobiol Dis. 2019;130:104481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31136814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, Baker L, Belleville S, Brodaty H, Brucki SM, et al.  World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078–1094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32627328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, et al.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672–2713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3778669</ArticleId>
            <ArticleId IdType="pubmed">21778438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67:505–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19358976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry. 2006;11:721–736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16786033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, Perry JR, Boehme KL, Walter S, Kauwe JS, et al.  Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLoS Med. 2015;12:e1001841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4469461</ArticleId>
            <ArticleId IdType="pubmed">26079503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res. 2006;28:605–611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16945211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Futch HS, Croft CL, Truong VQ, Krause EG, Golde TE. Targeting psychologic stress signaling pathways in Alzheimer's disease. Mol Neurodegener. 2017;12:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5479037</ArticleId>
            <ArticleId IdType="pubmed">28633663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juszczak GR, Stankiewicz AM. Glucocorticoids, genes and brain function. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:136–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29180230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zorn JV, Schür RR, Boks MP, Kahn RS, Joëls M, Vinkers CH. Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis. Psychoneuroendocrinology. 2017;77:25–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28012291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev. 2012;36:1376–1381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22390915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson RS, Bienias JL. Mendes de Leon CF, Evans DA, Bennett DA: Negative affect and mortality in older persons. Am J Epidemiol. 2003;158:827–835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14585760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porsteinsson AP, Tariot PN, Schneider LS. Mood Disturbances in Alzheimer's Disease. Semin Clin Neuropsychiatry. 1997;2:265–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10320470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller EA, Rosenheck RA, Schneider LS: Caregiver burden, health utilities, and institutional service use in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;27:382–393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3204397</ArticleId>
            <ArticleId IdType="pubmed">21560160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005;57:128–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15987548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandy S, Ikonomovic MD, Mitsis E, Elder G, Ahlers ST, Barth J, Stone JR, DeKosky ST. Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener. 2014;9:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4249716</ArticleId>
            <ArticleId IdType="pubmed">25231386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeKosky ST, Asken BM. Injury cascades in TBI-related neurodegeneration. Brain Inj. 2017;31:1177–1182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6218169</ArticleId>
            <ArticleId IdType="pubmed">28981345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mez J, Stern RA, McKee AC. Chronic Traumatic Encephalopathy. Semin Neurol. 2020;40:351–352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32906179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology–a bidirectional relationship. Nat Rev Neurol. 2014;10:115–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3979317</ArticleId>
            <ArticleId IdType="pubmed">24366271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, et al.  The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science. 2019;363:880–884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6410369</ArticleId>
            <ArticleId IdType="pubmed">30679382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klunk WE, Mathis CA. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol. 2008;21:683–687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637561</ArticleId>
            <ArticleId IdType="pubmed">18989113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22749065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4970664</ArticleId>
            <ArticleId IdType="pubmed">27371494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mormino EC, Toueg TN, Azevedo C, Castillo JB, Guo W, Nadiadwala A, Corso NK, Hall JN, Fan A, Trelle AN, et al: Tau PET imaging with (18)F-PI-2620 in aging and neurodegenerative diseases. Eur J Nucl Med Mol Imaging 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7755737</ArticleId>
            <ArticleId IdType="pubmed">32572562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsai RM, Bejanin A, Lesman-Segev O, LaJoie R, Visani A, Bourakova V, O'Neil JP, Janabi M, Baker S, Lee SE, et al.  (18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11:13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6357510</ArticleId>
            <ArticleId IdType="pubmed">30704514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Betthauser TJ. AD molecular: Imaging tau aggregates with positron emissions tomography. Prog Mol Biol Transl Sci. 2019;165:107–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31481160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, et al.  Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142:1063–1076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6439328</ArticleId>
            <ArticleId IdType="pubmed">30753379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, et al.  Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9:e-1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3733252</ArticleId>
            <ArticleId IdType="pubmed">23360977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiner MW, Aisen PS, Jack CR, Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, et al.  The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6:202–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2927112</ArticleId>
            <ArticleId IdType="pubmed">20451868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. Mol Neurodegener. 2021;16:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7893769</ArticleId>
            <ArticleId IdType="pubmed">33608044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vergallo A, Megret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, et al.  Plasma amyloid beta 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimers Dement. 2019;15:764–775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31113759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F, et al.  Combination of plasma amyloid beta(1–42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7523295</ArticleId>
            <ArticleId IdType="pubmed">32988409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fandos N, Perez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, Doecke J, Fowler C, Masters CL, Sarasa M, Group AR  Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 2017;8:179–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5602863</ArticleId>
            <ArticleId IdType="pubmed">28948206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14:989–997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6097897</ArticleId>
            <ArticleId IdType="pubmed">29626426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, Stomrud E, Palmqvist S, Mattsson-Carlgren N, Hansson O: Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7653537</ArticleId>
            <ArticleId IdType="pubmed">33165506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR., Jr The transformative potential of plasma phosphorylated tau. Lancet Neurol. 2020;19:373–374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32333888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Illan-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, Grinberg LT, Spina S, Kramer J, Ramos EM, et al: Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer's disease. Neurology 2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7884995</ArticleId>
            <ArticleId IdType="pubmed">33199433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, Wermeling P, Sedaghat S, Ikram MK, Waziry R, et al.  Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain. 2020;143:1220–1232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7174054</ArticleId>
            <ArticleId IdType="pubmed">32206776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen TB, Lee YJ, Lin SY, Chen JP, Hu CJ, Wang PN, Cheng IH. Plasma Abeta42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment. Sci Rep. 2019;9:13984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6764975</ArticleId>
            <ArticleId IdType="pubmed">31562355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622225</ArticleId>
            <ArticleId IdType="pubmed">23332364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, Ghetti B, Martins RN, Masters CL, Mayeux R, et al.  Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014;6:226ra230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4038930</ArticleId>
            <ArticleId IdType="pubmed">24598588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oxtoby NP, Young AL, Cash DM, Benzinger TLS, Fagan AM, Morris JC, Bateman RJ, Fox NC, Schott JM, Alexander DC. Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain. 2018;141:1529–1544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5920320</ArticleId>
            <ArticleId IdType="pubmed">29579160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewenstein DA, Curiel RE, Greig MT, Bauer RM, Rosado M, Bowers D, Wicklund M, Crocco E, Pontecorvo M, Joshi AD, et al.  A Novel Cognitive Stress Test for the Detection of Preclinical Alzheimer Disease: Discriminative Properties and Relation to Amyloid Load. Am J Geriatr Psychiatry. 2016;24:804–813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5026876</ArticleId>
            <ArticleId IdType="pubmed">27160985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3266529</ArticleId>
            <ArticleId IdType="pubmed">22265587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1759558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HG, Casadesus G, Zhu X, Joseph JA, Perry G, Smith MA. Perspectives on the amyloid-beta cascade hypothesis. J Alzheimers Dis. 2004;6:137–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15096697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HG, Castellani RJ, Zhu X, Perry G, Smith MA. Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective? Int J Exp Pathol. 2005;86:133–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2517413</ArticleId>
            <ArticleId IdType="pubmed">15910547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res. 2006;3:75–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16472207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn) 2016;22:404–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5390929</ArticleId>
            <ArticleId IdType="pubmed">27042901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Apostolova LG, Dutton RA, Dinov ID, Hayashi KM, Toga AW, Cummings JL, Thompson PM. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006;63:693–699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16682538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol. 2005;4:752–759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16239182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707–1712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14676044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Allen M, Is O, Reddy JS, Tutor-New FQ, Castanedes Casey M, Carrasquillo MM, Oatman SR, Min Y, Asmann YW, et al: Alzheimer's disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions. J Clin Invest 2021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8759790</ArticleId>
            <ArticleId IdType="pubmed">34813500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan YW, Al-Ouran R, Mangleburg CG, Perumal TM, Lee TV, Allison K, Swarup V, Funk CC, Gaiteri C, Allen M, et al.  Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Rep. 2020;32:107908.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7428328</ArticleId>
            <ArticleId IdType="pubmed">32668255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, et al.  Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769–780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7405761</ArticleId>
            <ArticleId IdType="pubmed">32284590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011;3:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3109410</ArticleId>
            <ArticleId IdType="pubmed">21211070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3474597</ArticleId>
            <ArticleId IdType="pubmed">22784036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garringer HJ, Murrell J, D'Adamio L, Ghetti B, Vidal R. Modeling familial British and Danish dementia. Brain Struct Funct. 2010;214:235–244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8375673</ArticleId>
            <ArticleId IdType="pubmed">19779737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal R, Revesz T, Rostagno A, Kim E, Holton JL, Bek T, Bojsen-Moller M, Braendgaard H, Plant G, Ghiso J, Frangione B. A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in a Danish kindred. Proc Natl Acad Sci U S A. 2000;97:4920–4925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC18333</ArticleId>
            <ArticleId IdType="pubmed">10781099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature. 1999;399:776–781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10391242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123:1847–1855.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3635732</ArticleId>
            <ArticleId IdType="pubmed">23635781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004;10:1055–1063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15459709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9641683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737–7741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC22742</ArticleId>
            <ArticleId IdType="pubmed">9636220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med. 2000;51:543–569.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10774481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16756495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris GP, Clark IA, Vissel B. Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun. 2014;2:135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4207354</ArticleId>
            <ArticleId IdType="pubmed">25231068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robakis NK. What Do Recent Clinical Trials Teach Us About the Etiology of AD. Adv Exp Med Biol. 2020;1195:167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32468473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellani RJ, Plascencia-Villa G, Perry G. The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Lab Invest. 2019;99:958–970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30760863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kametani F, Hasegawa M. Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. Front Neurosci. 2018;12:25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5797629</ArticleId>
            <ArticleId IdType="pubmed">29440986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makin S. The amyloid hypothesis on trial. Nature. 2018;559:S4–S7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30046080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selkoe DJ. The Molecular Pathology of Alzheimer's Disease. Neuron. 1991;6:487–498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1673054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett. 2004;11:213–228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15182223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Aging. 2006;27:570–575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16481071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE, Janus C. Homing in on intracellular Abeta? Neuron. 2005;45:639–642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15748837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3234452</ArticleId>
            <ArticleId IdType="pubmed">22229116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labzin LI, Heneka MT, Latz E. Innate Immunity and Neurodegeneration. Annu Rev Med. 2018;69:437–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29106805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Invest. 2017;127:3240–3249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5669553</ArticleId>
            <ArticleId IdType="pubmed">28862638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McManus RM, Heneka MT. Role of neuroinflammation in neurodegeneration: new insights. Alzheimers Res Ther. 2017;9:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5336609</ArticleId>
            <ArticleId IdType="pubmed">28259169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al.  Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3887148</ArticleId>
            <ArticleId IdType="pubmed">10858586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGeer PL, McGeer EG, Kawamata T, Yamada T, Akiyama H. Reactions of the immune system in chronic degenerative neurological diseases .[Review] Can J Neurol Sci. 1991;18:376–379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1933684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eikelenboom P, Rozemuller JM, van Muiswinkel FL. Inflammation and Alzheimer's disease: relationships between pathogenic mechanisms and clinical expression. Exp Neurol. 1998;154:89–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9875271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filipello F, Morini R, Corradini I, Zerbi V, Canzi A, Michalski B, Erreni M, Markicevic M, Starvaggi-Cucuzza C, Otero K, et al.  The Microglial Innate Immune Receptor TREM2 Is Required for Synapse Elimination and Normal Brain Connectivity. Immunity. 2018;48:979–991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29752066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilton DK, Dissing-Olesen L, Stevens B. Neuron-Glia Signaling in Synapse Elimination. Annu Rev Neurosci. 2019;42:107–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31283900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai B, Vanderwall D, Li Y, Wang X, Poudel S, Wang H, Dey KK, Chen PC, Yang K, Peng J. Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. Mol Neurodegener. 2021;16:55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8359598</ArticleId>
            <ArticleId IdType="pubmed">34384464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG. Pathological proteins in senile plaques. Tohoku J Exp Med. 1994;174:269–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7761992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:9649–9653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC47627</ArticleId>
            <ArticleId IdType="pubmed">8415756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham CR, Selkoe DJ, Potter H. A serine protease inhibitor, alpha-1 anti-chymotrypsin, is a component of amyloid deposits in Alzheimer's disease brain. Cell. 1988;52:487–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3257719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snow AD, Sekiguchi RT, Nochlin D, Kalaria RN, Kimata K. Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol. 1994;144:337–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1887140</ArticleId>
            <ArticleId IdType="pubmed">8311117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai B, Wang X, Li Y, Chen PC, Yu K, Dey KK, Yarbro JM, Han X, Lutz BM, Rao S, et al.  Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. Neuron. 2020;106:700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7322979</ArticleId>
            <ArticleId IdType="pubmed">32437656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14:133–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5829048</ArticleId>
            <ArticleId IdType="pubmed">29377008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M, Jucker M. Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med. 2013;5:194re192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23863834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM, et al.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med. 2020;26:398–407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7309367</ArticleId>
            <ArticleId IdType="pubmed">32161412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM, et al.  Tau Kinetics in Neurons and the Human Central Nervous System. Neuron. 2018;98:861–864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192252</ArticleId>
            <ArticleId IdType="pubmed">29772204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaeser SA, Hasler LM, Lambert M, Bergmann C, Bottelbergs A, Theunis C, Mercken M, Jucker M. CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 2022;143:287–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8742811</ArticleId>
            <ArticleId IdType="pubmed">34961894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strang KH, Golde TE, Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest. 2019;99:912–928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7289372</ArticleId>
            <ArticleId IdType="pubmed">30742061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alonso AD, Beharry C, Corbo CP, Cohen LS. Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimers Dement. 2016;12:1090–1097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27126544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26631930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, et al.  Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease. Neuron. 2018;99:925–940.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6240334</ArticleId>
            <ArticleId IdType="pubmed">30189209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracy TE, Madero-Perez J, Swaney DL, Chang TS, Moritz M, Konrad C, Ward ME, Stevenson E, Huttenhain R, Kauwe G, et al: Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell 2022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8857049</ArticleId>
            <ArticleId IdType="pubmed">35063084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol. 2003;62:137–145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12578223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, Sato Y, Nixon RA. Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy. J Neurosci. 2011;31:7817–7830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3351137</ArticleId>
            <ArticleId IdType="pubmed">21613495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vickers JC, Chin D, Edwards AM, Sampson V, Harper C, Morrison J. Dystrophic neurite formation associated with age-related beta amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp Neurol. 1996;141:1–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8797662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan R, Shi Q, Hu X, Zhou X. Reticulon proteins: emerging players in neurodegenerative diseases. Cell Mol Life Sci. 2006;63:877–889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16505974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharoar MG, Shi Q, Ge Y, He W, Hu X, Perry G, Zhu X, Yan R. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer's disease. Mol Psychiatry. 2016;21:1263–1271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4887420</ArticleId>
            <ArticleId IdType="pubmed">26619807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharoar MG, Hu X, Ma XM, Zhu X, Yan R. Sequential formation of different layers of dystrophic neurites in Alzheimer's brains. Mol Psychiatry. 2019;24:1369–1382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7204504</ArticleId>
            <ArticleId IdType="pubmed">30899091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, et al.  Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010;30:2636–2649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2841957</ArticleId>
            <ArticleId IdType="pubmed">20164348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, Dengler C, et al.  Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 2018;24:29–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5760353</ArticleId>
            <ArticleId IdType="pubmed">29200205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng C, Trojanowski JQ, Lee VM. Protein transmission in neurodegenerative disease. Nat Rev Neurol. 2020;16:199–212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32203399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaquer-Alicea J, Diamond MI. Propagation of Protein Aggregation in Neurodegenerative Diseases. Annu Rev Biochem. 2019;88:785–810.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30917002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawas CH, Corrada MM. Successful cognitive aging: What the oldest-old can teach us about resistance and resilience. Neurology. 2020;95:329–330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32699142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ridge PG, Karch CM, Hsu S, Arano I, Teerlink CC, Ebbert MTW, Gonzalez Murcia JD, Farnham JM, Damato AR, Allen M, et al.  Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer's disease resilience. Genome Med. 2017;9:100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5706401</ArticleId>
            <ArticleId IdType="pubmed">29183403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snitz BE, Chang Y, Tudorascu DL, Lopez OL, Lopresti BJ, DeKosky ST, Carlson MC, Cohen AD, Kamboh MI, Aizenstein HJ, et al.  Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology. 2020;95:e984–e994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7668550</ArticleId>
            <ArticleId IdType="pubmed">32699143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4095696</ArticleId>
            <ArticleId IdType="pubmed">25024750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017;26:735–739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5576861</ArticleId>
            <ArticleId IdType="pubmed">28460541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golde TE, DeKosky ST, Galasko D. Alzheimer's disease: The right drug, the right time. Science. 2018;362:1250–1251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30545877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 2020;6:e12050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7364858</ArticleId>
            <ArticleId IdType="pubmed">32695874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, et al.  Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010;6:89–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4298995</ArticleId>
            <ArticleId IdType="pubmed">20298968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;26(Suppl 3):321–329.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3343739</ArticleId>
            <ArticleId IdType="pubmed">21971471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, et al.  Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013;169:737–743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3880800</ArticleId>
            <ArticleId IdType="pubmed">24016464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4049292</ArticleId>
            <ArticleId IdType="pubmed">24648338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. Mol Neurodegener. 2021;16:2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7805095</ArticleId>
            <ArticleId IdType="pubmed">33441154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seto M, Weiner RL, Dumitrescu L, Hohman TJ. Protective genes and pathways in Alzheimer's disease: moving towards precision interventions. Mol Neurodegener. 2021;16:29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8086309</ArticleId>
            <ArticleId IdType="pubmed">33926499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexander GC, Knopman DS, Emerson SS, Ovbiagele B, Kryscio RJ, Perlmutter JS, Kesselheim AS. Revisiting FDA Approval of Aducanumab. N Engl J Med. 2021;385:769–771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34320282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gandy S, Knopman DS, Sano M. Talking points for physicians, patients and caregivers considering Aduhelm(R) infusion and the accelerated pathway for its approval by the FDA. Mol Neurodegener. 2021;16:74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8569969</ArticleId>
            <ArticleId IdType="pubmed">34736482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDade E, Llibre-Guerra JJ, Holtzman DM, Morris JC, Bateman RJ. The informed road map to prevention of Alzheimer Disease: A call to arms. Mol Neurodegener. 2021;16:49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8293489</ArticleId>
            <ArticleId IdType="pubmed">34289882</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
